Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy. [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the efficacy and safety of HR19042 capsules for IgA nephropathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• HR19042

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: IgA Nephropathy | Phase 2 | Status: COMPLETED